Posted by Michael Wonder on 16 Oct 2024
Sellas announces US FDA rare paediatric disease designation granted to galinpepimut-S for the treatment of paediatric acute myeloid leukaemia
15 October 2024 - Galinpepimut-S currently investigated in Phase 3 REGAL trial in adult AML patients – interim analysis anticipated in Q4 2024.
Sellas Life Sciences today announced that the US FDA has granted rare paediatric disease designation to galinpepimut-S, an immunotherapeutic targeting Wilms Tumour-1, for the treatment of paediatric acute myeloid leukaemia.
